Supernus (SUPN) Stock Price, News & Analysis
Ticker history: INDV became SUPN (Indivior Pharmaceuticals, Inc.) on . Earlier news and filings retain their original names and dates. View INDV history.
What Changed
Price Move History
- Daily moves over 5%
- 12 252 sessions, November 11, 2025 to November 11, 2026
- Largest daily move
- -22.4% close of November 3, 2026
- 1-year change
- -5.2% closing prices, November 11, 2025 to November 11, 2026
- 1-month change
- -17.8% closing prices, October 9, 2026 to November 11, 2026
Company Description
Supernus, Inc. Overview
Supernus, Inc. (SUPN) is a pharmaceutical company associated in public records with opioid use disorder treatment, postpartum depression treatment collaboration activity, material agreements, shareholder voting matters and capital-structure disclosures. The company is headquartered in Rockville, Maryland.
Supernus has a documented corporate transformation history. Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. completed a business combination on November 2, 2026. Under that transaction, Supernus continued as the surviving corporation and became a wholly owned subsidiary of Indivior; Indivior was then renamed Supernus, Inc.
The Indivior business is described as focused on evidence-based treatment for opioid use disorder and on long-acting injectable treatments for OUD. SEC filings also identify SUBOXONE Tablets and SUBUTEX Tablets as products manufactured for Indivior under a copacker supply agreement.
Supernus also has a documented role in ZURZUVAE (zuranolone), a treatment described for moderate or severe postpartum depression in adults following childbirth. ZURZUVAE was discovered by Sage Therapeutics, and Biogen and Sage entered a collaboration to jointly develop and commercialize it in the United States. Supernus Pharmaceuticals completed its acquisition of Sage Therapeutics in July 2025 and became Biogen’s U.S. collaboration partner for ZURZUVAE.
Key Business and Filing Themes
- Opioid use disorder: Indivior describes its business focus around evidence-based treatment and long-acting injectable treatments for OUD.
- Postpartum depression: Supernus is identified as the U.S. collaboration partner with Biogen for ZURZUVAE after acquiring Sage Therapeutics.
- Material agreements: SEC filings document supply arrangements and other material-event disclosures tied to the combined company’s pharmaceutical operations.
- Capital structure: Company filings include convertible note disclosures and adjustments tied to corporate actions.
Stock Performance
Supernus (SUPN) closed at $29.45 on November 11, 2026. Over the past 12 months, the price has lost 5.2%.
SUPN Metrics & Rankings
Price returns through November 11, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Supernus has 10 recent news articles, with the latest published 2 days ago. Of the recent coverage, 7 articles coincided with positive price movement and 3 with negative movement. Key topics include acquisition, earnings, earnings date, dividends. View all SUPN news →
SEC Filings
Supernus has filed 10 recent SEC filings, including 10 Form 4. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all SUPN SEC filings →
Insider Radar
Insider buying activity at Supernus over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Supernus generated $1.2B in revenue in FY2025, retaining a 80.2% gross margin, operating income reached $262.0M (21.1% operating margin), and net income was $210.0M, reflecting a 17.0% net profit margin. Diluted earnings per share stood at $1.64. The company generated -$27.0M in operating cash flow. The current ratio was 0.71, measuring current assets divided by current liabilities.
Upcoming Events
Jefferies fireside chat
Second supplier approval
Qelbree patent expirations
Qelbree patent expirations
Qelbree patent expiration
Supernus has 5 upcoming scheduled events. The next event, "Jefferies fireside chat", is scheduled for November 16, 2026 (in 4 days). Investors can track these dates to stay informed about potential catalysts that may affect the SUPN stock price.
Short Interest History
Short interest in Supernus (SUPN) currently stands at 4.6 million shares, up 14.2% from the previous reporting period, representing 7.9% of the shares outstanding. Since November 2025, short interest has decreased by 11.2%.
Days to Cover History
Days to cover for Supernus (SUPN) currently stands at 3.4 days, down 30.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 2.8 to 10.1 days.
SUPN Company Profile & Sector Positioning
Supernus (SUPN) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing SUPN often look at related companies in the same sector, including ANI Pharmaceuticals, Inc. (ANIP), Eton Pharmaceutcials, Inc. (ETON), Pacira BioSciences, Inc. (PCRX), Alvotech (ALVO), and Cronos Group Inc. (CRON). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SUPN's relative position within its industry.